Potassium Nitrate

Evidence Level: L5

Predicted Indications: 2

Potassium Nitrate

Pharmacist Assessment Report

Potassium Nitrate: From Dental Hypersensitivity Products to Meningococcal Infection

One-Sentence Summary

Potassium nitrate is marketed in India as an ingredient in dental gels and toothpastes. The TxGNN model predicts it may be effective for meningococcal infection, but no clinical trials and no publications currently support this prediction. It rests on a model score alone.

Quick Overview

Item	Content
Original Indication	Not recorded (no approved indication text in the registrations)
Predicted New Indication	Meningococcal infection
TxGNN Prediction Score	0.9961
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on the registrations, potassium nitrate is a single-ingredient component of oral-care products (dental gels and toothpastes) in India. No original indication is recorded for it.

One speculative rationale is that potassium nitrate is an inorganic nitrate salt. It can be reduced to nitrite and then to nitric oxide (NO), and NO and related reactive nitrogen species have general antimicrobial activity. This is not specific to Neisseria meningitidis and is not supported by any data compiled for this report.

Meningococcal infection is an acute, life-threatening invasive disease. It is treated with established antibiotics and prevented by vaccines. A high TxGNN score alone does not justify repurposing a nitrate salt for this condition.

A second prediction, sclerosing cholangitis (score 0.9921), also has no clinical trials or literature. Its proposed link, nitrate-derived NO signalling affecting vascular tone, inflammation or biliary epithelial function, is equally unsupported.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

There are 20 valid single-ingredient registrations, with no combination products and none cancelled. The five main ones are listed below. Approved indication text is not recorded for any of them.

Authorization Number	Product Name	Dosage Form	Manufacturer
151674	Nitra Gel Mint	Dental gel, 100 g tube	Micro Labs Ltd
117360	Kyodent Dental Gel	Dental gel, 50 g tube	Lifekyor Pharmaceuticals
61782	Dent-X Toothpaste (Medicated)	Toothpaste, 100 g tube	Cascade India Pharmaceuticals
65292	Dentosmith Toothpaste	Toothpaste, 50 g tube	Nusmith Pharma Pvt. Ltd
164072	Orasafe Dental Gel	Gel, 50 g tube	Age Biotech

Safety Considerations

Knowledge-graph contraindication signal: The TxGNN knowledge graph (PrimeKG) links potassium nitrate to dental fluorosis as a contraindication. This comes from graph edges, not from label text.

No package insert warnings, contraindications or drug interaction data were available. Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on the model score only (Evidence Level L5). There are no clinical trials or publications, and no mechanism data. Established antibiotic treatment and vaccines exist for meningococcal infection. All current products are topical oral-care formulations, and route compatibility with a systemic infection has not been assessed.

To proceed, the following is needed:

Mechanism of action data for potassium nitrate
Package insert warnings and contraindications for the marketed products
Independent preclinical evidence of activity against Neisseria meningitidis
Assessment of route and formulation compatibility with the proposed indication
Clarification of the dental fluorosis contraindication signal
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.